AFFINITY ADSORBENTS FOR THE REMOVAL OF HIV-I FROM BLOOD

用于去除血液中 HIV-I 的亲和吸附剂

• 批准号: 3359142
• 负责人: DAVID H BING
• 金额: $ 39.45万
• 依托单位: IMMUNE DISEASE INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-07-01 至 1991-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3359142
• 关键词: CD4 molecule; adsorption; blood filtration; glycoproteins; human immunodeficiency virus 1; human tissue; protein structure; synthetic peptide; virus antigen; virus envelope; virus protein; virus receptors

It is proposed to develop an affinity adsorbent system which can be used to remove HIV-1 antigens and/or virus from solution. The membrane will use a novel ligand, namely the T lymphocyte CD4 receptor for the HIV-1. This protein has recently been cloned and expressed as a fully soluble 50 kd protein which can combine specifically in solution with the gp120 env protein of HIV-1. The experimental plan will be to use novel chemical modification protocols to immobilize this protein on solid phase membrane materials. The immobilized receptor will be fully characterized according to its binding affinity and specificity for purified gp120 and HIV-1 as compared to other viruses which are found in blood (e.g., Epstein Barr, Cytomegalovirus). We will also attempt to use synthetic peptides, the sequence of which is based on the sequence of the HIV env proteins, to ascertain in competition experiments the active center of the viral receptor. These results should provide the experimental basis for designing HIV-1 specific blood compatible filter or adsorbent materials which could be introduced at appropriate steps in the blood collection process or in the manufacture of therapeutic plasma derivatives.

建议开发一种亲和吸附系统 用于从溶液中去除 HIV-1 抗原和/或病毒。 这 膜将使用一种新型配体，即T淋巴细胞CD4 HIV-1 的受体。这种蛋白质最近被克隆并 表达为完全可溶的 50 kd 蛋白质，可以结合 特别是在含有 HIV-1 的 gp120 env 蛋白的溶液中。 这 实验计划将使用新型化学修饰 将该蛋白质固定在固相膜上的方案 材料。 固定化受体将得到充分表征 根据其对纯化 gp120 的结合亲和力和特异性 和 HIV-1 与血液中发现的其他病毒相比 （例如，Epstein Barr，巨细胞病毒）。 我们还将尝试使用 合成肽，其序列基于 HIV 包膜蛋白的序列，以在竞争中确定 实验病毒受体的活性中心。 这些结果 应该为设计HIV-1特异性提供实验基础 血液相容性过滤器或吸附材料 在血液采集过程中的适当步骤引入或 用于制造治疗性血浆衍生物。